Trending Medical and health breaking news FDA to Review Topical PDE4-Inhibitor Roflumilast for Psoriasis

Trending Medical and well being breaking information FDA to Evaluate Topical PDE4-Inhibitor Roflumilast for Psoriasis

The Food and Drug Administration has accepted a new drug application (NDA) for roflumilast, a topical phosphodiesterase type 4 (PDE4) inhibitor for treating psoriasis in adults and adolescents, according to a statement from the manufacturer. Roflumilast cream (also known as ARQ-151) is a small molecule inhibitor of PDE4, an enzyme that increases proinflammatory mediators and decreases anti-inflammatory mediators. PDE4…